6819-41-6

Basic information

• Product Name: Sodium propanolate
• Synonyms: SODIUM N-PROPOXIDE;Sodium propanolate;1-Propanol,sodiumsalt;sodiumn-propoxide,snp,in;sodiumn-propoxide,snp,inn-propanol;Sodium propoxide;Sodiumpropoxide;Sodium n-propoxide, in n-propanol
• CAS NO: 6819-41-6
• Molecular Formula: C₃H₇O*Na
• Molecular Weight: 82.08
• EINECS: 229-895-8
• Mol File: 6819-41-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 97°C
• Flash Point: 23°C
• Appearance: colorless liquid
• Density: 0,866 g/cm3
• Vapor Pressure: 26.3mmHg at 25°C
• CAS DataBase Reference: Sodium propanolate(CAS DataBase Reference)
• NIST Chemistry Reference: Sodium propanolate(6819-41-6)
• EPA Substance Registry System: Sodium propanolate(6819-41-6)

Safety Data

• Statements: 10-14-34
• Safety Statements: 16-26-36
• RIDADR: 2924
• TSCA: Yes
• HazardClass: 4.1
• PackingGroup: II
• Hazardous Substances Data: 6819-41-6(Hazardous Substances Data)

Usage

General Description

Sodium propanolate is a chemical compound with the molecular formula C3H7NaO. It is a white to off-white solid that is highly soluble in water. It is commonly used as a base in organic synthesis reactions, where it serves as a catalyst for various reactions such as esterification and transesterification. It is also used as a reagent for the synthesis of pharmaceuticals and other organic compounds. Sodium propanolate is a strong base and can react violently with water, releasing flammable hydrogen gas in the process. It should be handled with care and stored in a cool, dry place away from moisture and heat sources.

InChI:InChI=1/C3H7O.Na/c1-2-3-4;/h2-3H2,1H3;/q-1;+1

Upstream product

• 71-23-8 propan-1-ol 

Downstream Products

• 107924-46-9 β-propoxy-chalcone 
• 505-84-0 dipropoxymethane 
• 2315-68-6 propyl benzoate 
• 1471-03-0 allyl propyl ether 
• 20680-10-8 1-(1-ethoxyethoxy)-propane 
• 14144-41-3 β-Propoxy-propionsaeure-propylester 
• 82245-67-8 5-nitro-2-propoxybenzonitrile 
• 69081-89-6 24.24-diphenyl-choladien-(5.23)-ol-(3β) 
• 628-32-0 ethylpropylether 
• 111-43-3 Dipropyl ether 
• 854256-33-0 1-methyl-4-nitro-2-n-propoxybenzene 
• 16533-50-9 m-propoxyphenol 
• 56106-37-7 1,3-di(n-propoxy)benzene 
• 100-46-9 benzylamine 

Relevant articles and documents

Preparation method for low residual granular sodium alkoxide or potassium alcoholate

The invention provides a preparation method for low residual granular sodium alkoxide or potassium alcoholate. The method includes using sodium or potassium and alcohol as raw materials, mixing the mixture with a solvent, reacting in inert gas atmosphere by using a microwave heating method, and removing the residual alcohol and solvent in the presence of microwave after the reaction to get the granular sodium alkoxide or potassium alcoholate. The microwave frequency is 2450 +/- 50 MHz. The method can prepare sodium alkoxide or potassium alcoholate with low residual solvent, and the prepared sodium alkoxide or potassium alcoholate is large granular solid, so that the development from powdered product to granular product can be realized, and the problems of residual solvent and potential risk troubled human for a long time can be overcome.

Bisaryl-sulfonamides

Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPARγ or PPARδ. In particular, the compounds of the invention modulate the function of PPARγ or PPARδ. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.

QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS

The present invention relates to quinazolinones of formula (I) wherein R1 is hal; a); b); or c); X is N or CR8; R2 is hal; nitro; C1-C6alkylcarbonyl; C1-C6alkyl or C3-C6cycloalkyl; R3 is C1-C6alkyl; C1-C6alkoxy or amino; and wherein the further radicals have the meanings as defined in the specification, which compounds exhibit human vanilloid antagonistic activity; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.